Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients
Journal of the Pakistan Medical Association · 2024
DOI: 10.47391/jpma.10480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pakistan Medical Association, 2024. Verfasst von Ishtiaq Ahmad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mardan Medical complex, Bacha Khan Medical College, Mardan, Pakistan. Hauptthemen laut MEDLINE: Dexamethasone, Cytokine Release Syndrome, Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The current study was planned to explore the potential synergistic role of the co-administration of sarilumab and dexamethasone in reducing blood biomarkers associated with cytokine release syndrome in hospitalised patients of coronavirus disease-2019. The sample comprised 22 patients hospitalised with severe and critical severity levels and who were treated with sarilumab and dexamethasone. Positive responses were seen in blood biomarkers, including decreased interleukin-6 alpha levels and improved oxygen saturation. Tumour necrosis factor, D-dimer, C-reactive protein, ferritin and lymphocyte count also showed positive responses in patients who survived than those who died. Lactate dehydrogenase levels fluctuated with improvement among the survivors, but had limited effectiveness in those who died. The findings suggested promising avenues for future treatment strategies in patients with severe coronavirus disease-2019 and cytokine release syndrome. Key Words: Sarilumab, Dexamethasone, Biomarkers, Cytokine release syndrome, COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Mardan Medical complex, Bacha Khan Medical College, Mardan, Pakistan.
Zitieren
APA
Ahmad, I., & Hamidullah (2024). Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.10480
Vancouver
Ahmad I, Hamidullah. Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients. Journal of the Pakistan Medical Association. 2024. doi:10.47391/jpma.10480
BibTeX
@article{Ahmad2024,
author = {Ahmad, Ishtiaq and Hamidullah, Hamidullah},
title = {Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients},
journal = {Journal of the Pakistan Medical Association},
year = {2024},
doi = {10.47391/jpma.10480}
}
EUVIMED